Compare · JUNS vs NVO
JUNS vs NVO
Side-by-side comparison of Jupiter Neurosciences Inc. (JUNS) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both JUNS and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $188.38B, about 22399.3x JUNS ($8.4M).
- Over the past year, JUNS is down 76.4% and NVO is down 45.0% - NVO leads by 31.4 points.
- JUNS has been more active in the news (26 items in the past 4 weeks vs 8 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 0 for JUNS).
- Company
- Jupiter Neurosciences Inc.
- Novo Nordisk A/S
- Price
- $0.23-3.25%
- $43.59+3.33%
- Market cap
- $8.4M
- $188.38B
- 1M return
- -38.79%
- -5.86%
- 1Y return
- -76.37%
- -44.97%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2024
- News (4w)
- 26
- 8
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest JUNS
- Presenting on Emerging Growth Conference 93 Day 2 on June 11; Register to live stream
- SEC Form PRE 14A filed by Jupiter Neurosciences Inc.
- Presenting on Emerging Growth Conference 93 Day 1 on June 10; Register to live stream
- SEC Form 424B3 filed by Jupiter Neurosciences Inc.
- Jupiter Neurosciences Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- SEC Form 4 filed by Director Brady Allison W
- SEC Form 4 filed by Chief Scientific Officer Hayward Marshall A.
- SEC Form 4 filed by Chief Financial Officer Elmasri Saleem
- SEC Form 4 filed by President and COO Silva Alison D.
- SEC Form 4 filed by Director Kampf Julie B.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care